N@N

Robyn Karnauskas Maintained (BIIB) at Hold with Decreased Target to $290 on, May 2nd, 2018

Robyn Karnauskas of Citigroup, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $360 to $290 on, May 2nd, 2018.

Robyn has made no other calls on BIIB in the last 4 months.

There are 9 other peers that have a rating on BIIB. Out of the 9 peers that are also analyzing BIIB, 2 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Geoff Meacham of "Barclays" Downgraded from Buy to Hold on, Thursday, April 5th, 2018
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $350 on, Wednesday, January 24th, 2018

These are the ratings of the 7 analyists that currently disagree with Robyn

---

• Brian Skorney of "Baird" Upgraded from Hold to Buy on, Wednesday, April 25th, 2018
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $369 on, Wednesday, April 25th, 2018
• Ian Somaiya of "BMO Capital" Maintained at Buy with Decreased Target to $393 on, Monday, March 5th, 2018
• Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $433 on, Monday, February 5th, 2018
• Carter Gould of "UBS" Upgraded from Hold to Strong Buy on, Wednesday, January 31st, 2018
• Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $400 on, Friday, January 26th, 2018
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $363 on, Friday, January 26th, 2018

Contributing Sources

---